Literature DB >> 33552861

Nitric Oxide-Driven Nanomotor for Deep Tissue Penetration and Multidrug Resistance Reversal in Cancer Therapy.

Mi Mi Wan1, Huan Chen1, Zhong Da Wang2, Zhi Yong Liu1, Yue Qi Yu1, Lin Li2, Zhuo Yue Miao1, Xing Wen Wang1, Qi Wang1, Chun Mao1, Jian Shen1, Jia Wei2.   

Abstract

Poor permeation of therapeutic agents and multidrug resistance (MDR) in solid tumors are the two major challenges that lead to the failure of the current chemotherapy methods. Herein, a zero-waste doxorubicin-loaded heparin/folic acid/l-arginine (HFLA-DOX) nanomotor with motion ability and sustained release of nitric oxide (NO) to achieve deep drug penetration and effective reversal of MDR in cancer chemotherapy is designed. The targeted recognition, penetration of blood vessels, intercellular penetration, special intracellular distribution (escaping from lysosomes and accumulating in Golgi and nucleus), 3D multicellular tumor spheroids (3D MTSs) penetration, degradation of tumor extracellular matrix (ECM), and reversal of MDR based on the synergistic effects of the motion ability and sustained NO release performance of the NO-driven nanomotors are investigated in detail. Correspondingly, a new chemotherapy mode called recognition-penetration-reversal-elimination is proposed, whose effectiveness is verified by in vitro cellular experiments and in vivo animal tumor model, which can not only provide effective solutions to these challenges encountered in cancer chemotherapy, but also apply to other therapy methods for the special deep-tissue penetration ability of a therapeutic agent.
© 2020 The Authors. Advanced Science published by Wiley‐VCH GmbH.

Entities:  

Keywords:  cancer therapy; deep‐penetration; degradation of tumor extracellular matrix; multidrug resistance; nanomotors; nitric oxide

Year:  2020        PMID: 33552861      PMCID: PMC7856908          DOI: 10.1002/advs.202002525

Source DB:  PubMed          Journal:  Adv Sci (Weinh)        ISSN: 2198-3844            Impact factor:   16.806


  41 in total

1.  The molecule of the year.

Authors:  D E Koshland
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

Review 2.  In vitro and ex vivo strategies for intracellular delivery.

Authors:  Martin P Stewart; Armon Sharei; Xiaoyun Ding; Gaurav Sahay; Robert Langer; Klavs F Jensen
Journal:  Nature       Date:  2016-10-13       Impact factor: 49.962

3.  Enhanced Drug Delivery by Nanoscale Integration of a Nitric Oxide Donor To Induce Tumor Collagen Depletion.

Authors:  Xiao Dong; Hai-Jun Liu; Hai-Yi Feng; Si-Cong Yang; Xue-Liang Liu; Xing Lai; Qin Lu; Jonathan F Lovell; Hong-Zhuan Chen; Chao Fang
Journal:  Nano Lett       Date:  2019-01-29       Impact factor: 11.189

4.  Novel angiogenesis therapeutics by redox injectable hydrogel - Regulation of local nitric oxide generation for effective cardiovascular therapy.

Authors:  Long Binh Vong; Thang Quoc Bui; Tsutomu Tomita; Hiroaki Sakamoto; Yuji Hiramatsu; Yukio Nagasaki
Journal:  Biomaterials       Date:  2018-03-13       Impact factor: 12.479

Review 5.  Timeline: Chemotherapy and the war on cancer.

Authors:  Bruce A Chabner; Thomas G Roberts
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

6.  Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.

Authors:  Jianan Shen; Qianjun He; Yu Gao; Jianlin Shi; Yaping Li
Journal:  Nanoscale       Date:  2011-09-05       Impact factor: 7.790

Review 7.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

8.  A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors.

Authors:  Jianbing Liu; Linlin Song; Shaoli Liu; Shuai Zhao; Qiao Jiang; Baoquan Ding
Journal:  Angew Chem Int Ed Engl       Date:  2018-10-23       Impact factor: 15.336

Review 9.  Targeting and isolation of cancer cells using micro/nanomotors.

Authors:  Weiwei Gao; Berta Esteban-Fernández de Ávila; Liangfang Zhang; Joseph Wang
Journal:  Adv Drug Deliv Rev       Date:  2017-09-09       Impact factor: 15.470

10.  iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer.

Authors:  Naiqing Ding; Zhengyun Zou; Huizi Sha; Shu Su; Hanqing Qian; Fanyan Meng; Fangjun Chen; Shiyao Du; Shujuan Zhou; Hong Chen; Lianru Zhang; Ju Yang; Jia Wei; Baorui Liu
Journal:  Nat Commun       Date:  2019-03-22       Impact factor: 14.919

View more
  4 in total

1.  Nanozyme-Triggered Cascade Reactions from Cup-Shaped Nanomotors Promote Active Cellular Targeting.

Authors:  Xin Wang; Zhongju Ye; Shen Lin; Lin Wei; Lehui Xiao
Journal:  Research (Wash D C)       Date:  2022-06-19

2.  Cascade-activatable NO release based on GSH-detonated "nanobomb" for multi-pathways cancer therapy.

Authors:  Yi Feng; Hanxi Zhang; Xiaoxue Xie; Yu Chen; Geng Yang; Xiaodan Wei; Ningxi Li; Mengyue Li; Tingting Li; Xiang Qin; Shun Li; Fengming You; Chunhui Wu; Hong Yang; Yiyao Liu
Journal:  Mater Today Bio       Date:  2022-05-13

Review 3.  Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.

Authors:  Xiao Wei; Mingzhu Song; Weijie Li; Jing Huang; Guang Yang; Yi Wang
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

4.  Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors.

Authors:  Xin Yang; Yifan Wang; Si Chen; Shuang Zhang; Chunying Cui
Journal:  Int J Nanomedicine       Date:  2021-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.